[Endometrial cancer. Clinico-surgical classification and treatment results (analysis of 134 patients)]

The prognostic factors of Endometrial cancer at The General Hospital of Mexico, in accordance with the Surgical Pathologic Staging System of the International Federation of Gynecology and Obstetrics (FIGO, are reported here. One hundred and thirty four patients treated with conventional procedures, were evaluated for end results and in 127 cases, it was applied The Surgical-Pathologic Staging System of The International Federation of Gynecology and Obstetrics (FIGO). We had a follow-up without evidence of disease from 24 months to 10 years with a median of 30 months, in 58/105 adenocarcinomas (55.2%); 5/11 Adenoacanthomas (45.4%) and 4/14 Adenosquamous carcinomas, (28.5%). Same evolution was observed in 36/72 patients with age equal or less than 60 years, (50.0%) and 17/43 with age equal or more than 61 years, (39.5%. Using the current FIGO Staging System, the disease-free Survival was 51.9% (66/127 patients). This number includes 39/51, 76.4% for Stage I, (18/21 Ia, 90%; 13/15 Ib, 86.6% and 8/16 Ic, 50% P = 0.003); 17/23 cases: 73.9% for Stage II, (5/6 IIa, 83.3% and 12/17 IIb, 70.5%); 10/37 cases: 27.0% for Stage III, (5/14 IIIa 35.7%; 2/6IIIb, 33.3% and 3/17 IIc, 17.6%) and 1/17: 5.8% for Stage IV. P = 0.001. The current FIGO Staging System is a useful instrument for predicting natural evolution of endometrial carcinomas. In this series the survival was adversely affected by increasing Stage and age. A poor prognosis in pelvic tumors was related by a deep invasion of myometrial and by parametrial invasion.